Overview


According to FutureWise analysis the market for checkpoint inhibitors in 2023 is US$ 27.71 billion, and is expected to reach US$ 105.01 billion by 2031 at a CAGR of 18.10%.

A checkpoint inhibitor is a medication that disables the proteins that the body's immune system uses to prevent cancer cells from being destroyed. A type of medication known as a checkpoint inhibitor is used in immunotherapy to help block the proteins found on tumor cells that interfere with the immune system's ability to fight disease. T-cells are one type of immune cell that actively combats cancerous cells. T cells include proteins that either activate or suppress the immune system, depending on the protein. Checkpoints are what they are called. T-cells can activate or deactivate depending on the checkpoint they are at. The switch-off checkpoints limit the immune responses' potency and occasionally even prevent the T cells from destroying the cancer cells when cancer cells produce large amounts of proteins. The T-cells can attack the cancer cells when the checkpoint inhibitor prevents the checkpoints from binding with their companion proteins. Checkpoint inhibitors primarily consist of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cells, and other medication types. Anticancer checkpoint drugs such as PD-1 and PD-L1 inhibitors prevent the immune checkpoint proteins PD-1 and PDL1 from acting on cell surfaces. It is used to treat cancers of the lung, kidney, blood, bladder, melanoma, and other organs, and it is employed in a variety of industries, including hospitals, retail pharmacies, and internet pharmacies. During the projected period, the market for checkpoint inhibitors is predicted to expand due to the increase in cancer cases worldwide. Due to the rise in demand for effective cancer therapeutics, favourable reimbursement policies offered by manufacturers and insurance providers in some nations, and the increased prevalence of cancer worldwide, checkpoint inhibitors are predicted to experience significant market growth during the forecast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Checkpoint Inhibitors Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share, and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the study conducted by FutureWise research analysts, the Checkpoint Inhibitors Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche
  • Sanofi
  • MerckCo., Inc.
  • BeiGene Ltd
  • Shanghai Jhunsi Biosciences Ltd.
  • Incyte Corporation

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • PD-1 (Programmed Cell Death Protein 1)
  • PD-Ll(Programmed Death-ligand 1)
  • CTLA-4 (Cytotoxic Lymphocyte-associated Antigen)

By Therapeutic Application

  • Lung Cancer
  • Melanoma
  • Squarnous Cell Carcinoma
  • Urothelial Carcinoma
  • Blood Cancer
  • Other Therapeutic Applications

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Checkpoint Inhibitors Market By Drug Class, By Therapeutic Application, By Distribution Channel and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Checkpoint Inhibitors Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Checkpoint Inhibitors Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Checkpoint Inhibitors Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Checkpoint Inhibitors Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. PD-1 (Programmed Cell Death Protein 1)
        2. PD-Ll(Prograrnmed Death-ligand 1)
        3. CTLA-4 (Cytotoxic Lymphocyte-associated Antigen)

  • 8.   Checkpoint Inhibitors Market, By Therapeutic Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Lung Cancer
        2. Melanoma
        3. Squarnous Cell Carcinoma
        4. Urothelial Carcinoma
        5. Blood Cancer
        6. Other Therapeutic Applications

  • 9.   Checkpoint Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies

  • 10.   North America Checkpoint Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Checkpoint Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Checkpoint Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Checkpoint Inhibitors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca PLC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bristol-Myers Squibb Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eli Lilly and Company
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline Plc
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. F. Hoffmann-La Roche
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Sanofi
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. MerckCo., Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. BeiGene Ltd
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Shanghai Jhunsi Biosciences Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Incyte Corporation
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients